Dydrogesterone (DrugBank: Dydrogesterone)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-005129-10-FI (EUCTR) | 27/01/2015 | 12/12/2014 | Multiple Sclerosis, menopause and hormone replacement therapy | Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis | Multiple sclerosis MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852 MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Femoston 2/10 Product Name: Femoston 2/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE Trade Name: Femoston 1/10 Product Name: Femoston 1/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE | Irina Elovaara | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | Finland |